Skip Navigation


European Heart Journal Advance Access originally published online on December 8, 2004
European Heart Journal 2005 26(2):107-109; doi:10.1093/eurheartj/ehi042
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/2/107    most recent
ehi042v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Macphee, C. H.
Right arrow Articles by Nelson, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macphee, C. H.
Right arrow Articles by Nelson, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal vol. 26 no. 2 © The European Society of Cardiology 2004; all rights reserved.

An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction

Colin H. Macphee1,* and Jeanenne J. Nelson2

1Department of Vascular Biology, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA
2Department of Worldwide Epidemiology, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA

* Corresponding author. Tel.: +1 610 270-7227; fax: +1 610 270-6206 E-mail address: colin.h.macphee@gsk.com

This editorial refers to ‘Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up’{dagger} by E.S. Brilakis et al., on page 137

The first 10% of the full text of this article appears below.

Over the past 50 years, the age-adjusted mortality rate from cardiovascular disease has decreased substantially. Despite the improved mortality rate, there is evidence that actual cardiovascular event rates remain relatively unchanged (i.e. more people are surviving acute events), and heart disease and stroke continue to be leading causes of death in Western societies.1 Intensive research efforts are currently under way with the goal of further reducing the global burden of cardiovascular disease. An improved understanding of vascular biology and the pathogenesis of atherosclerosis—including the role of inflammatory processes—may prove helpful in achieving this goal.

Atherosclerosis is a condition involving numerous complex processes within the vessel wall that can be characterized as an inflammatory response to injury. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up
Emmanouil S. Brilakis, Joseph P. McConnell, Ryan J. Lennon, Ahmad A. Elesber, Jeffrey G. Meyer, and Peter B. Berger
EHJ 2005 26: 137-144. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
U. Samanta and B. J. Bahnson
Crystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase: STRUCTURAL IMPLICATION TO LIPOPROTEIN BINDING AND CATALYSIS
J. Biol. Chem., November 14, 2008; 283(46): 31617 - 31624.
[Abstract] [Full Text] [PDF]